Boehringer Ingelheim Fremont, Inc.
About Boehringer Ingelheim Fremont, Inc.
Boehringer Ingelheim is a leading research-driven biopharmaceutical company, creating value through innovation in areas of high unmet medical need.
One of the world’s largest manufacturers of biopharmaceuticals, Boehringer Ingelheim is an industry pioneer and has produced more than 40 commercial biopharmaceuticals. Our contract manufacturing business, Boehringer Ingelheim BioXcellence™ reliably supplies innovative therapies that transform lives, today and for generations to come and creates solutions with its partners to improve patient health through its production network spanning the globe, from Biberach, Germany to Vienna, Austria, Shanghai, China and Boehringer Ingelheim Fremont Inc., in California, United States.
A mammalian cell culture center in the San Francisco Bay Area, Boehringer Ingelheim Fremont, Inc., has more than 600 scientists and specialists committed to research, development, and manufacturing to deliver high quality medicines for patients. Our modern facility offers high flexibility with stainless steel and single-use bioreactors for fed-batch and process intensification technology manufacturing. With the complete range of services, from cell line and strain development, including high expression systems, through process development and large-scale manufacturing, to Fill & Finish we help our customers to turn innovative biologic ideas into commercial reality.
Biopharmaceuticals - Competence and Experience for Medicines of the Future Over 35 years ago, Boehringer Ingelheim started developing and producing biopharmaceuticals as one of the first companies worldwide. Biopharmaceuticals are produced by using either mammalian cell cultures or microorganisms such as bacteria or yeast.
1014 articles about Boehringer Ingelheim Fremont, Inc.
-
Boehringer Ingelheim Corporation Licenses Drug Targets from Autoimmune Collaboration with Galapagos NV
7/17/2008
-
Boehringer Ingelheim Corporation Gains Access to Additional MorphoSys AG Technology
7/9/2008
-
Boehringer Ingelheim Corporation and GENEART AG Collaborate on Offering Design and Production Services for DNA Therapeutics and Vaccines
6/24/2008
-
ZoomMed Signs a Renewal Agreement With Boehringer Ingelheim Corporation
6/12/2008
-
Ingenuity Systems Announces Multi-Year Agreement With Boehringer Ingelheim Corporation
6/4/2008
-
Boehringer Ingelheim Corporation, Gilead Sciences, Inc. Agree to AIDS Drug Price Freeze
6/3/2008
-
Rentschler Biotechnologie GmbH & Co. Announces Cooperation with Boehringer Ingelheim Corporation
5/21/2008
-
Boehringer Ingelheim Corporation PRoFESS(R) Results Announced at XVII European Stroke Conference
5/14/2008
-
Boehringer Ingelheim Corporation and BioSpace Search for Scientists at Career Fair in Boston, Massachusetts
4/8/2008
-
Boehringer Ingelheim Corporation China Profits from Sinopharm Deal
4/1/2008
-
Boehringer Ingelheim Corporation Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population
3/31/2008
-
Image Solutions, Inc. (ISI)'s SaaS Approach to eCTD Submissions Helps Boehringer Ingelheim Corporation Meet FDA Submission Requirements in Record Time
3/27/2008
-
Image Solutions, Inc. (ISI)'s SaaS Approach to eCTD Submissions Helps Boehringer Ingelheim Corporation Meet FDA Submission Requirements in Record Time
3/27/2008
-
Pfizer Inc., Boehringer Ingelheim Corporation's Spiriva May Raise Risk of Stroke Says US FDA
3/19/2008
-
Boehringer Ingelheim Corporation Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
1/17/2008
-
Boehringer Ingelheim Corporation Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
11/28/2007
-
Vitae Pharmaceuticals, Inc. and Boehringer Ingelheim GmbH Announce a Major Collaboration to Develop and Commercialize Novel Treatments for Diabetes and Metabolic Diseases
10/15/2007
-
Boehringer Ingelheim Corporation Receives Top Honor as World's Most Respected Biopharmaceutical Employer in Science 2007 Top Employers Survey
10/12/2007
-
Boehringer Ingelheim Corporation's Aptivus(R) Capsules Granted Full Approval by the U.S. FDA
10/8/2007
-
Caliper Life Sciences, Inc. Develops Customized Transfection System for Boehringer Ingelheim Corporation
7/30/2007